Trovagene's (TROV) Liquid Biopsy Tests Will be Covered by BCBSIL

August 17, 2016 8:33 AM EDT

Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.

Trovagene, Inc. (Nasdaq: TROV), announced that it has signed an in-network provider agreement with the healthcare network Blue Cross Blue Shield of Illinois () establishing health benefit access to the full line of Trovagene's tests and services.

"The agreement with BCBSIL takes us a step further in the execution of our access and reimbursement strategy that includes establishing relationships with leading national and regional payors," said Bill Welch, Chief Executive Officer of Trovagene. "We are looking forward to offering oncologists and their patient's access to our Trovera™ urine and blood based liquid biopsy tests and enabling personalized cancer care."

Trovagene now has contracts with payors covering approximately 168 million lives. Increasing patient access by contracting with payors is one of the critical strategic components that support the adoption of Trovagene's clinical testing in late-stage solid tumor cancers.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Corporate News, Management Comments

Add Your Comment